Company Filing History:
Years Active: 2019-2021
Title: Simon Walz: Innovator in Cancer Immunotherapy
Introduction
Simon Walz is a prominent inventor based in Tuebingen, Germany. He has made significant contributions to the field of immunotherapy, particularly in the treatment of myeloma and other cancers. With a total of 7 patents to his name, Walz is recognized for his innovative approaches to cancer treatment.
Latest Patents
One of Simon Walz's latest patents focuses on "Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers." This invention relates to peptides, proteins, nucleic acids, and cells that are utilized in immunotherapeutic methods. Specifically, it addresses the immunotherapy of cancer, especially myeloma. The invention also discusses tumor-associated T-cell peptide epitopes, which can serve as active pharmaceutical ingredients in vaccine compositions that stimulate anti-tumor immune responses. Furthermore, it explores the potential of these peptides to stimulate T cells ex vivo and transfer them into patients. Peptides bound to molecules of the major histocompatibility complex (MHC) or peptides themselves can also be targets for antibodies, soluble T-cell receptors, and other binding molecules.
Career Highlights
Simon Walz is currently associated with Immatics Biotechnologies GmbH, where he continues to advance his research in cancer immunotherapy. His work has been instrumental in developing innovative solutions that enhance the effectiveness of cancer treatments.
Collaborations
Throughout his career, Walz has collaborated with notable colleagues, including Hans-Georg Rammensee and Daniel Johannes Kowalewski. These collaborations have further enriched his research and contributed to the advancement of immunotherapeutic methods.
Conclusion
Simon Walz is a key figure in the field of cancer immunotherapy, with a focus on innovative solutions that leverage cell epitopes for treatment. His contributions are paving the way for more effective cancer therapies, making a significant impact in the medical community.